| Identification | More | [Name]
Colchicine | [CAS]
64-86-8 | [Synonyms]
7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxybenzo[a]heptalen-9(5h)-one
ACETAMIDE, N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL-, (S)
COLCHICEINE METHYL ETHER
COLCHICINE
COLCHICINE, COLCHICUM AUTUMNALE
COLCHISOL
COLCIN
n-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)-acetamide
N-((S)-1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL)-ACETAMIDE
(S)-N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL)ACETAMIDE
7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxy-benzo(a)heptalen-9(5h)-on
7-alpha-h-colchicine
7alpha-h-colchicine
7alphaH-Colchicine
Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(alpha)heptalen-7-yl)-
acetamide,n-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(alpha)hepta
benzo(a)heptalen-9(5h)-one
Benzo(a)heptalen-9(5H)-one, 7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxy-
Colchicin
Colchicina | [EINECS(EC#)]
200-598-5 | [Molecular Formula]
C22H25NO6 | [MDL Number]
MFCD00078484 | [Molecular Weight]
399.44 | [MOL File]
64-86-8.mol |
| Chemical Properties | Back Directory | [Definition]
An alkaloid plant hormone. | [Appearance]
Colchicine is a pale yellow powder. It has little or no odor. It darkens on contact with light. | [Melting point ]
150-160 °C (dec.)(lit.)
| [alpha ]
-250 º (c=1, alcohol) | [Boiling point ]
522.37°C (rough estimate) | [density ]
1.2770 (rough estimate) | [refractive index ]
1.5614 (estimate) | [storage temp. ]
Poison room | [solubility ]
H2O: 10 mg/mL
| [form ]
powder
| [pka]
12.36(at 20℃) | [color ]
white to yellow with a green cast
| [Stability:]
Stable. Light sensitive. Incompatible with strong oxidizing agents. | [Water Solubility ]
45 g/L (20 ºC) | [Sensitive ]
Light Sensitive | [Usage]
An antimitotic agent that disrupts microtubles by binding to tubulin and preventing its polymerization. Stimulates the intrinsic GTPase activity of tubulin. Induces apoptosis in several normal and tumor cell lines and activates the JNK/SAPK signal | [Merck ]
14,2471 | [BRN ]
2228813 | [BCS Class]
3 | [InChIKey]
IAKHMKGGTNLKSZ-INIZCTEOSA-N | [LogP]
1.300 | [CAS DataBase Reference]
64-86-8(CAS DataBase Reference) | [NIST Chemistry Reference]
Colchicine(64-86-8) | [EPA Substance Registry System]
64-86-8(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
T+,T | [Risk Statements ]
R26/28:Very Toxic by inhalation and if swallowed . | [Safety Statements ]
S13:Keep away from food, drink and animal feeding stuffs .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [RIDADR ]
UN 1544 6.1/PG 1
| [WGK Germany ]
3
| [RTECS ]
GH0700000
| [TSCA ]
Yes | [HazardClass ]
6.1 | [PackingGroup ]
I | [HS Code ]
29399900 | [Safety Profile]
experimentally by most routes. Human
systemic effects: aplastic anemia, blood
pressure depression, body temperature
decrease, changes in kidney tubules,
dyspnea, flaccid paralysis without anesthesia,
gastrointestinal effects, kidney damage and
hemorrhaging, muscle contraction or
spasticity, muscle weakness, nausea or
vomiting, respiratory stimulation, and
somnolence. An experimental teratogen.
Experimental reproductive effects. A severe
eye irritant. Human mutation data reported.
Inhibits the formation of microtubules and
thus impairs cell division. When heated to
decomposition it emits toxic fumes of NOx. | [Hazardous Substances Data]
64-86-8(Hazardous Substances Data) | [Toxicity]
LD50 in rats (mg/kg): 1.6 i.v. (Rosenbloom, Ferguson); in mice (mg/kg): 4.13 i.v. (Beliles) |
| Raw materials And Preparation Products | Back Directory | [Preparation Products]
Acetamide, N,N'-[(7S,7bR,8aS,8bS,9aR,10S,16cS,16dR,16eR,16fS)-5,6,7,7b,8,8a,8b,9,9a,10,11,12,16c,16d,16e,16f-hexadecahydro-1,2,3,8a,8b,14,15,16-octamethoxy-8,9-dioxobisbenzo[3',4']cyclohepta[1',2':3,4]cyclobuta[1,2-c:1',2'-c']cyclobuta[1,2-a:4,3-a']dicyclopentene-7,10-diyl]bis--->GAMMA-LUMICOLCHICINE-->thiocolchicine |
| Hazard Information | Back Directory | [General Description]
Odorless or nearly odorless pale yellow needles or powder that darkens on exposure to light. Used to treat gouty arthritis, pseudogout, sarcoidal arthritis and calcific tendinitis. | [Reactivity Profile]
COLCHICINE(64-86-8) darkens on exposure to light. Incompatible with strong oxidizing agents. Also incompatible with mineral acids . | [Air & Water Reactions]
Slowly hydrolyzed in acidic solution, but unbuffered solutions are stable at 68°F for at least six months. Isomerizes on exposure to ultraviolet radiation. | [Hazard]
As little as 20 mg may be fatal if ingested. | [Health Hazard]
COLCHICINE is classified as super toxic. Probable oral lethal dose in humans is less than 5 mg/kg, i.e. less than 7 drops for a 70 kg (150 lb.) person. Death results from respiratory arrest. The fatal dose varies considerably; as little as 7 mg of colchicine has proved fatal. | [Potential Exposure]
Colchicine is a drug used to treat gouty arthritis, pseudogout, sarcoidal arthritis; and calcific tendonitis. | [Fire Hazard]
Stable. | [First aid]
This material is an alkaloid. If this chemical gets into the eyes, remove any contact lenses at once and irrigate immediately for at least 15 minutes, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts the skin, remove contaminated clothing and wash immediately with soap and water. Seek medical attention immediately. If this chemical has been inhaled, remove from exposure, begin rescue breathing (using universal precautions, including resuscitation 894 Colchicine mask) if breathing has stopped and CPR if heart action has stopped. Transfer promptly to a medical facility. When this chemical has been swallowed, get medical attention. Give large quantities of water and induce vomiting. Do not make an unconscious person vomit. Medical observation is recommended for 24 to 48 hours after breathing overexposure, as pulmonary edema may be delayed. As first aid for pulmonary edema, a doctor or authorized paramedic may consider administering a drug or other inhalation therapy | [Shipping]
UN1544 Alkaloids, solid, n.o.s. or Alkaloid salts, solid, n.o.s. poisonous, Hazard Class: 6.1; Labels: 6.1- Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials | [Incompatibilities]
Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides, mineral acids. Keep away from light. | [Description]
Colchicine is a pale-yellow powder that is obtained from various species of Colchicum, primarily Colchicum
autumnale L. Its total chemical synthesis has been achieved, but the primary source of colchicine currently remains alcohol
extraction of the alkaloid from the corm and seed of C. autumnale L. It darkens on exposure to light and possesses | [Physical properties]
Appearance: colchicine exists in white or light-yellow crystal powder with no smell, and it is seldom prone to absorb moisture. Melting point: it becomes dark when it is exposed to light, and it melts at 87–89?°C. Solubility: this product is soluble in chloroform or ethanol and it dissolves in water. However, the semihydrate crystal can form in certain concentrations. The product is hardly soluble in ether. Specific optical rotation: ?121° (0.9?g/100?mL, chloroform, 589.3?nm, 17?°C). | [History]
Meadow saffron (Colchicum) is recorded to treat rheumatic swelling on ancient
Egyptian medical papyrus in 1500 B.C.. According to De Materia Medica written by Pedanius Dioscorides in the first century, extract of Meadow saffron is used
in treating gout. London Pharmacopoeia in 1618 recorded that colchicine is also
applied to treat gout.
In 1820, the ingredient was first isolated by the French chemist P.S. Pelletier and
J.B. Caventou. In 1833, it was purified and named by Geiger. Michael Dewar
guessed that there are two seven-membered rings in colchicine in 1945. Murray
Vernon King et al. determined the structure of colchicine by X-ray diffraction in
1952. In 1959, Albert Eschenmoser integrated the product successfully
Colchicine tablet and raw material are approved mostly in domestic in 2010. The
tablet produced by Taiwan manufacturers is approved for being listed in mainland
of China in 2012. The raw material made by Indian obtained the approval in 2013.
There are three kinds of colchicine approved by FDA: with the combination of probenecid, it is prior to be approved. The others are tablet (2009) and capsule (2014). | [Indications]
Colchicine, an alkaloid obtained from the autumn
crocus, has long been used and is relatively selective for
the treatment of acute gouty arthritis. Unlike many of
the newer agents for use in gout, colchicine has minimal
effects on uric acid synthesis and excretion; it decreases
inflammation associated with this disorder. It is thought
that colchicine somehow prevents the release of the
chemotactic factors and/or inflammatory cytokines from
the neutrophils, and this in turn decreases the attraction
of more neutrophils into the affected area .The
ability of colchicine to bind to leukocyte microtubules
in a reversible covalent complex and cause their depolymerization
also may be a factor in decreasing the
attraction of the motile leukocytes into the inflamed
area. | [Biological Functions]
Acting on
polymorphonuclear leukocytes and diminishing phagocytosis, it inhibits the production of lactic acid, causing an
increase in the pH of synovial tissue and, thus, a decrease in urate deposition, because uric acid is more soluble at
the higher pH. Additionally, colchicine inhibits the release of lysosomal enzymes during phagocytosis that also
contributes to the reduction of inflammation. Because colchicine does not lower serum urate levels, it has been found
to be beneficial to combine colchicine with a uricosuric agent, particularly probenecid. It is a potent drug, being
effective at doses of approximately 1 mg, but doses as small as 7 mg have caused fatalities. | [Biological Activity]
Plant-derived alkaloid that binds to tubulin and depolymerizes microtubules. | [Biochem/physiol Actions]
Colchicine interacts with albumin and binds to tubulin. Its association with tubulin impacts autophagic vacuole fusion with lysosomes. It inhibits tyrosine kinases and phospholipases. Colchicine may be useful for treating acute coronary syndromes. It is prescribed for treating rheumatologic conditions including familial mediterranean fever (FMF) and acute gouty arthritis. | [Mechanism of action]
Colchicine is rapidly absorbed after oral administration
and tends to concentrate in the spleen, kidney,
liver, and gastrointestinal tract. Leukocytes also avidly
accumulate and store colchicine even after a single intravenous
injection. Since colchicine can accumulate in
cells against a concentration gradient, it is postulated
that an active transport process may be involved in its
cellular uptake. The drug is metabolized, primarily in
the liver, by deacetylation. Fecal excretion plays a major
role in colchicine elimination, since it and its metabolites
are readily secreted into the bile. Only about 15 to
30% of the drug is eliminated in the urine except in patients
with liver disease; urinary excretion is more important
in these individuals. | [Pharmacokinetics]
Colchicine is absorbed on oral administration, with peak plasma levels being attained within 0.5 to 2 hours after
dosing. Plasma protein binding is only 31%. It concentrates primarily in the intestinal tract, liver, kidney, and spleen
and is excreted primarily in the feces, with only 20% of an oral dose being excreted in the urine. It is retained in the
body for considerable periods of time, being detected in the urine and leukocytes for 9 to 10 days following a single
dose. | [Pharmacology]
The drug
can be given intravenously as well as orally, but care
must be exercised, since extravasated drug may result in
local sloughing of skin and subcutaneous tissues. Relief
of pain and inflammation usually occurs within 48
hours. Small doses of colchicine can be used during
asymptomatic periods to minimize the reappearance or
severity of acute attacks. It should be used with caution
in patients with preexisting compromised heart, kidney,
gastrointestinal tract, and liver disease.
Diarrhea, nausea, vomiting, and abdominal pain are
the major limiting side effects that ultimately determine
the tolerated dosage. These symptoms occur in approximately
80% of patients who take colchicine, especially in those taking high dosages. The hepatobiliary recycling
of colchicine and its antimitotic effect on cells that
are rapidly turning over, such as those of the intestinal
epithelium, account for its gastrointestinal toxicity.
Gastrointestinal symptoms generally intervene before
the appearance of more serious toxicity and thereby
provide a margin of safety in drug administration.
Ingestion of large doses of colchicine may be followed
by a burning sensation in the throat, bloody diarrhea,
shock, hematuria, oliguria, and central nervous system
(CNS) depression. | [Anticancer Research]
It is a natural toxic secondary metabolite, extracted from Colchicum genus plants. Itprevents gastric cancer by upregulating the dual specificity phosphatase 1 (DUSP1)gene. It is also reported to upregulate transforming growth factor beta 2 (TGF-β2)and A-kinase anchoring protein 12 (AKAP12) in hepatocellular carcinoma (Singhet al. 2016b). | [Clinical Use]
The major use of colchicine is as an antiinflammatory
agent in the treatment of acute gouty arthritis; it is not effective
in reducing inflammation in other disorders. It also
can be used to prevent attacks. Since colchicine is so rapidly
effective in relieving the acute symptoms of gout
(substantial improvement is achieved within hours), it
has been used as a diagnostic aid in this disorder.
Therapy with colchicine is usually begun at the first
sign of an attack and is continued until symptoms subside,
adverse gastrointestinal reactions appear, or a
maximum dose of 6 to 7 mg has been reached. | [Veterinary Drugs and Treatments]
In veterinary medicine, colchicine has been proposed as a treatment
in small animals for amyloidosis.
For colchicine to be effective,
however, it must be given early in the course of the disease and
it will be ineffective once renal failure has occurred. At the time of
writing, no conclusive evidence exists for its efficacy for this indication
in dogs.
Colchicine has also been proposed for treating chronic hepatic
fibrosis presumably by decreasing the formation and increasing the
breakdown of collagen. | [Drug interactions]
Potentially hazardous interactions with other drugs
Anti-arrhythmics: possible increased risk of toxicity
with amiodarone.
Antibacterials: possible increased risk of toxicity
with azithromycin, clarithromycin, erythromycin and
telithromycin - suspend or reduce dose of colchicine,
avoid concomitant use in renal or hepatic failure.
Antifungals: possible increased risk of toxicity with
itraconazole and ketoconazole - suspend or reduce
dose of colchicine, avoid concomitant use in renal or
hepatic failure.
Antivirals: possible increased risk of toxicity with
atazanavir, indinavir, ritonavir and telaprevir
- suspend or reduce dose of colchicine, avoid
concomitant use in renal or hepatic failure.
Calcium-channel blockers: possible increased risk of
toxicity with diltiazem and verapamil - suspend or
reduce dose of colchicine, avoid concomitant use in
renal or hepatic failure.
Cardiac glycosides: possible increased risk of
myopathy with digoxin.
Ciclosporin: risk of myopathy or rhabdomyolysis,
also increased blood-ciclosporin concentrations
and nephrotoxicity - suspend or reduce dose of
colchicine, avoid concomitant use in renal or hepatic
failure.
Grapefruit juice: possible increased risk of toxicity.
Lipid-regulating drugs: possible increased risk of
myopathy with fibrates and statins. | [Environmental Fate]
Colchicine binds to tubulin and prevents its polymerization
into microtubules, subsequently disrupting microtubule function.
Consequently, it alters nuclear structure, intracellular
transport, and cytoplasmic motility, ultimately causing cell
death. Colchicine is a potent inhibitor of cellular mitosis. | [Metabolism]
Metabolism occurs primarily in the liver, with the major metabolite being the amine resulting from amide
hydrolysis. | [storage]
Store at RT | [Purification Methods]
Commercial material contains up to 4% desmethylcolchicine. Purify colchicine by chromatography on alumina and eluting with CHCl3 [Ashley & Harris J Chem Soc 677 1944]. Alternatively, an acetone solution on alkali-free alumina has been used, and eluting with acetone [Nicholls & Tarbell J Am Chem Soc 75 1104 1953]. It crystallises as yellow needles from EtOAc or CHCl3 with solvent of crystallisation which can be removed at ~70o. It is soluble in Et2O (0.5%), *C6H6 (1%) and H2O (4%). It is sold as “Colgout” for the treatment of gout and binds to tubulin. [Schreiber et al. Helv Chim Acta 44 540 1961, Scott et al. Tetrahedron 21 3605 1965, van Tamelen et al. Tetrahedron 14 8 1961, Beilstein 14 IV 946.] | [Toxicity evaluation]
No information is currently available on breakdown in soil,
groundwater, or surface water. Colchicine alkaloids withstand
storage, drying, and boiling.
Ingestion is the most common route of both accidental and
intentional exposure to colchicine. It is available as an oral
tablet and solution for injection. | [References]
1) Merck 14:2471 |
| Questions And Answer | Back Directory | [Alkaloids]
Colchicine is a kind of alkaloid extracted from the crom or seed of the lily family plants, Colchicum autumnale, and is naturally presented in the Liliaceae Garland and Iphigenia with the contents being 0.11% and 0.1%. It is pale yellow needle crystals. It has slight odor and bitter taste with the melting point being 157 ℃. It is soluble in cold water, alcohol, chloroform and formaldehyde with poor solubility in hot water and is not easily soluble in benzene and ether. It is almost insoluble in petroleum ether with the pH of its 0.5% solution being 5.9. Hydrolysis with ammonia can reduce the toxicity. Colchicine is known to inhibit cell mitosis and has anti-tumor effect. In 1889, Italian scholar Pernice had first discovered the effect of colchicine on mitosis. He had described the metaphase of the lining cells in the stomach and intestines of dogs can be blocked colchicine with spindle being damaged and chromosome action paralyzed as well as a large number of abnormal mitotic cells existing in their metaphase. This abnormal division caused by the colchicine is known as colchicine mitosis (referred as the C mitosis). In the mutagenesis analysis of karyotyping and polyploid, colchicine is a most widely used chemicals. Its water concentration has a positive correlation with its action role. The higher the concentration is, the stronger the effect will be. Various kinds of plants and different organizations are known to have different response to colchicine. Generally, for young and rapidly divided organizations (e.g. germ of germinating seeds), the processing time can be shorter and the concentration should be lower; on the contrary, the processing time can be longer and the concentration should be higher. The effective concentration of colchicine treatment is 0.01 to 0.4% with the concentration of 0.2% having the mostly wide range. For example, if we drop 0.2 to 0.4% of colchicine solution on the diploid watermelon seedlings growing point once a day for four consecutive days, and keep the shade and humidity, you can induce tetraploid watermelon. For cereal crops such as rice, you can have robust seedling with four or more leaves cut an incision in the root neck with the degree within not cutting the growing point and immerse it into the 0.025 to 0.05% colchicine solution, submerge the incision, you can also obtain the tetraploid plants after 8 to 14 days (20 ℃). Currently, the colchicine is widely used for the chromosome doubling for haploid plants obtained from the culture of anther (powder), ovary culture.
| [Anti-gout drug]
Colchicine has a good efficacy in treating acute gout and can quickly relieve pain and can prevent the onset of arthritis with its mechanism of action related to the inhibition of white blood cells and proliferation activities and the effect on lysosomal release.
The pharmacological effects of this product are through reducing activity and phagocytosis of leukocytes in the inflammatory tissue and reducing the inflammation caused by uric acid crystals, and thus playing effects of inflammation, swelling and pain effect, therefore it has selective anti-inflammatory effect on the acute gouty arthritis. In addition the product is also a kind of mitosis toxins with strong inhibitory effect of cell division, making the cells stopped in their division time and leading to tumor cell death, and therefore being used for cancer treatment. This product is easily absorbed after oral administration with 30% binding to plasma proteins and the plasma concentration reaching peak at 0.5 to 2 hours after oral administration. The plasma concentration peak after oral administration of 2mg is about 2.2ng/ml. It can play its efficacy at 12 hours after the administration in the case of acute gout and the efficacy can sustain 50 to 70 hours. The drug concentration in the isolated neutrophils is higher than the plasma concentrations and can maintain for as long as 10 days. This product is mostly metabolized by the liver with the metabolite and the prototype drug being excreted by the bile, further being reabsorbed through the intestinal tract with the unabsorbed part being discharged by the gut. The rest, about 10% to 20%, can be excreted through renal via urine.
This product does not affect the formation, dissolution and excretion of uric acid salt thereby has no effect on lowering the blood uric acid content. It is clinically used for the treatment of acute gouty arthritis attack, prevention of recurrent episodes of acute gouty arthritis, familial Mediterranean fever, leukemia, skin cancer, Hodgkin's disease, and aplastic anemia. It can also applied to the specific treatment of M cycle of various kinds of malignant diseases such as the breast cancer, lung cancer, esophageal cancer, cervical cancer, nasopharyngeal carcinoma, Hodgkin's disease, chronic myelogenous leukemia, and skin cancer.
The above information is edited by the chemicalbook of Dai Xiongfeng.
| [Side effects]
The adverse reaction has significant correlation with the dosage.
1. Gastrointestinal reactions: nausea, abdominal pain, diarrhea, vomiting and loss of appetite are common early side effects with the incidence being up to 80%. In severe cases, there may be dehydration and electrolyte imbalance. Upon such kind of performance, the drug should be immediately discontinued. Patients of long-term usage can get severe hemorrhagic gastroenteritis or malabsorption syndrome.
2. The blood system reactions: long-term medication can cause agranulocytosis, thrombocytopenia, aplastic anemia, and sometimes threaten the life.
3. Other toxic reactions; it is mainly manifested as urinary tract irritation symptoms such as urinary frequency, urgency, dysuria, hematuria, oliguria, or even renal failure. There may also be symptoms such as stomach, throat or skin burning sensation, and fever, bloody diarrhea, mental changes, myasthenia gravis, and respiratory depression.
4. During the period of taking colchicine, we should pay attention to check blood and liver and kidney function. Patients of hematopoietic dysfunction, liver and kidney damage, heart disease and severe gastrointestinal disease should administer with caution. Pregnant women should be disabled.
5. Muscles, peripheral neuropathy: proximal muscle weakness, and elevated serum creatine kinase; there may also be peripheral nerve axonal polyneuropathy at the same time of damaged muscle cells, manifested as numbness, tingling and weakness; muscle neuropathy is rare, often occurs for people of long-term use in the prevention of gout and those with mild renal insufficiency.
| [Dosage and administration]
Tablets: 0.5 mg per tablet; injection: 1mg, 2mg.
1. for the treatment of acute gout: for adult who orally administers tablets, apply the first dose of 0.5~1 mg, then take 0.5~0.6 mg every 1 to 2 hours until the joint symptoms or gastrointestinal symptoms get alleviated when you can discontinue the treatment. Usually a total dose of 4~10 mg can play obvious efficacy. Note that the patients should administer the drug as early as possible to get excellent efficacy during the acute phase of medication. If the patients take intravenous injection with the first dose being 1~2mg, slowly inject with 20 mL of saline with the time of being no less than five minutes. If necessary, apply intravenous injection every 6 to 12 hours for 0.5~1 mg until it works with the total dose of 4~5 mg/d. Intravenous injection can give a better efficacy than oral administration, and can also significantly reduce the gastrointestinal reactions.
2. for the prevention of acute gout: Adults should take 0.5~0.6 mg of tablet per time with 2 times daily or intravenous injection of 1~2mg/d. 3. For the diagnosis test of gout: If the acute joints symptom gets alleviated after treatment, this will help confirm the diagnosis.
| [Hazardous characteristics]
Colchicine itself has a small toxicity, but after absorption, it can be metabolized (oxidized) in vivo to become the oxydicolchicine of a strong toxicity. It has a strong irritation effect on the digestive tract and can inhibit the blood cells, causing neutropenia deficiency and aplastic anemia. It can also cause paralysis on the nerve center and smooth muscle, resulting in vasodilation, and respiratory center paralysis and death. The human lethal dose of colchicine is 6mg~7mg. Mouse oral-LD was 66.6mg/kg; LD50-intraperitoneal injection of mice is 3.5mg/kg. LD50-subcutaneous injection of rat is 4mg/kg.
This product has been applied for treating acute gout for a long time. Later, it was found that it has a strong inhibitory effect on the cell division. Medically, it has been applied to the treatment of various cancers, such as breast cancer, cervical cancer, esophageal cancer, skin cancer, and chronic myelogenous leukemia. However, due to the high colchicine toxicity, in order to reduce the toxicity and improve the efficacy, people has modified the structure of colchicine with the toxicity of the resulting compounds being reduced, such as colchicine amine (TMCA, I), colchicine methylamine (Demecolcine II), it has now been used clinically.
Colchicine poisoning has a certain incubation period with symptoms often happening at 3d~6d after oral administration or injection. Symptoms include throat burning, nausea, vomiting, abdominal pain, diarrhea, watery stools, hematuria, urine retention, numbness, aching limbs, muscle cramps, hair loss, dilated pupils, and convulsion, paralysis of the central nervous system, and respiratory depression and death. In addition, it can also produce local reactions such as when the drug liquid is leaked out from the blood vessel upon injection, local tissue necrosis can occur. Poisoning is usually caused by ingestion or drug overdose. There are also individual cases in which people take it for suicide. The method of treatment is mainly symptomatic treatment. Patients of swallowing colchicine or patients of colchicine poisoning should be prohibited for the use of oxidants such as potassium permanganate to avoid generating a large number of colchicine oxide in the body which further increases the toxicity.
| [Chemical Properties]
It is pale yellow crystal or crystalline powder with bitter taste and the color being changed upon exposure to light.. M.p. is 157 ℃ (recrystallized from ethyl acetate), specific rotation [α] 17D-429 ° (1.72%, water),-121° (0.9%, chloroform). It has the maximum absorption wavelengths being 243nm and 350.5 nm in ethanol. This product is easily soluble in water, ethanol and chloroform, soluble in benzene and ether, but insoluble in petroleum ether. The 0.5% solution of this product is acidic. LD50 (mouse, intraperitoneal) is 6.1mg/kg.
| [Uses]
It can be used for the study of plant genetics; used as selenium reagent; clinically as anticancer drugs.
The product is a typical mitosis toxin. It can be used for treating acute gout and breast cancer. It can also be used as selenium reagent, for being applied to plant genetics and cancer research.
It is a kind of antineoplastic agents and anti-gout for being used for the treatment acute gout and for the treatment of tumors
| [Application in Acute Gouty Arthritis]
- Colchicine is an antimitotic drug that is highly effective in relieving acute gout attacks but has a low benefit-toxicity ratio. When colchicine is started within the first 24 hours of an acute attack, about two-thirds of patients respond within several hours. The likelihood of success decreases substantially if treatment is delayed longer than 48 hours after symptom onset.
- Oral colchicine causes dose-dependent GI adverse effects (nausea, vomiting, and diarrhea) in 50% to 80% of patients before relief of the attack. Non-GI adverse effects include neutropenia and axonal neuromyopathy, which may be worsened in patients taking other myopathic drugs (e.g., statins) or in those with renal insufficiency. Colchicine should not be used concurrently with macrolide antibiotics (especially clarithromycin) because reduced biliary excretion may lead to increased plasma colchicine levels and agranulocytosis.
- Colchicine should be reserved for patients with insufficient relief, intolerance, or contraindications to NSAIDs.
- The usual oral colchicine dose is 1 mg initially, followed by 0.5 mg every 1 hour until the joint symptoms subside, the patient develops abdominal discomfort or diarrhea, or a total dose of 8 mg has been given.
- IV colchicine should be avoided because it is associated with serious adverse effects (e.g., bone marrow suppression, tissue necrosis from local extravasation, disseminated intravascular coagulation, hepatocellular toxicity, and renal failure). If considered necessary, the recommended initial IV dose is 2 mg (if renal function is normal) diluted in 10 to 20 mL of normal saline administered slowly over 10 to 20 minutes in a secure, freeflowing IV line to avoid extravasation. This may be followed by two additional doses of 1 mg each at 6-hour intervals, with the total dose not exceeding 4 mg. After a full IV course, patients should not receive colchicine by any route for at least 7 days.
| [Production method]
This product is a kind of alkaloid extracted from the crom or seed of the lily family plants, Colchicum autumnale. The Colchicum autumnale powder was heated under reflux with 85% ethanol extraction for 4h, the resulted ethanol solution was concentrated under reduced pressure to a semi-gum, dilute with distilled water, with 10% sulfuric acid acidified filtrate with extraction by chloroform, and then concentrate the chloroform extract, the resulted crude colchicine obtained by crystallization was subject to re-crystallization to obtain the finished product. Calculated from the Colchicum autumnale powder, the total yield is 0.15%. In foreign countries, it is mostly extracted from the crom of the Liliaceae Colchicum genus Colchicum bulbs.
Take the bulbs and seeds of Iphigenia indica or Colchicum autumnale as raw material; obtain the final product with ethanol extraction and refining.
| [Category]
toxic substances
| [Toxicity grading]
toxic
| [Acute toxicity]
intravenous-rat LD50: 1.6 mg/kg; Oral-Mouse LD50: 5.886 mg/kg
| [Irritation data]
eyes-rabbit 1%/3 days Severe
| [Flammability and hazard characteristics]
combustible with fire causing decomposition into toxic nitrogen oxide fumes
| [Storage properties]
warehouse: cold, ventilated and dry; and food raw materials stored separately
| [Extinguishing media]
Water, carbon dioxide, dry, sandy soil
|
|
|